![Rolf Schneider-Günther](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Mr. Rolf Schneider-Günther is the founder of BayTech Venture Capital.
Before BayTech Venture Capital he was with Atlas Venture which he had joined in 1992.
He became Managing Director Germany and General Partner in the same year.
His track record includes a substantial number of investments which resulted in extremely successful exits via their IPOs such as Morphosys AG, Micronas AG, WaveLight Laser Technologie AG, Medigene AG, Actelion AG and Cardima Inc.
He started his career as CFO of a german high-technology company which is a world leader in chemical fiber processing.
In 1986 he joined Merck, Sharpe & Dohme as director of Business Development and moved to director of Strategic Planning and Controlling in 1988.
Rolf Schneider-Günther holds a masters degree and a Ph.D.
in Business Administration and studied Pharmacology at the Universities of Regensburg and Munich.
Ehemalige bekannte Positionen von Rolf Schneider-Günther
| Unternehmen | Position | Ende |
|---|---|---|
BayernLB Capital Partner GmbH
 BayernLB Capital Partner GmbH Investment ManagersFinance BayTech invests in early-stage technology and life sciences companies in Western Europe. The firm targets high-growth startups primarily in Germany and France, and focuses on sectors including communications, software, semiconductors, internet-enabled businesses, medical technology and biotechnology. They seek to invest in potential international market leaders. Their investment criteria include a knowledgeable management team, a potential for high-growth in an attractive market, a sustainable competitive advantage and a clear exit opportunity via IPO or trade sale within five years. BayTech's investment approach is hands-on from day one. The firm's strategy includes getting involved in the decision processes of a potential investee before committing capital, to actively shape their strategy and refine their business plan. The firm initially invests between EUR 1 and 3 million, either as the lead investor or in syndication. They may participate in subsequent financing rounds as well. Board representation is an investment prerequisite. | Chief Investment Officer | 31.01.2012 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
18
Beziehungen ersten Grades
1
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
BayernLB Capital Partner GmbH
BayernLB Capital Partner GmbH Investment ManagersFinance BayTech invests in early-stage technology and life sciences companies in Western Europe. The firm targets high-growth startups primarily in Germany and France, and focuses on sectors including communications, software, semiconductors, internet-enabled businesses, medical technology and biotechnology. They seek to invest in potential international market leaders. Their investment criteria include a knowledgeable management team, a potential for high-growth in an attractive market, a sustainable competitive advantage and a clear exit opportunity via IPO or trade sale within five years. BayTech's investment approach is hands-on from day one. The firm's strategy includes getting involved in the decision processes of a potential investee before committing capital, to actively shape their strategy and refine their business plan. The firm initially invests between EUR 1 and 3 million, either as the lead investor or in syndication. They may participate in subsequent financing rounds as well. Board representation is an investment prerequisite. | Finance |
